Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hemagglutinin subunit HA2 of the A/Indonesia/05/2005 (H5N1) influenza virus is a critical component of the viral envelope glycoprotein responsible for mediating host cell entry [UniProt Q207Z6]. While the HA1 subunit facilitates initial binding to sialic acid receptors, the HA2 subunit (the stalk or stem region) undergoes a dramatic pH-dependent conformational change within the endosome to trigger membrane fusion [Ekiert et al., 2009]. This fusion process allows the viral ribonucleoproteins to enter the host cytoplasm, initiating infection [Sui et al., 2009]. Because the HA2 stalk region is significantly more conserved across different influenza strains than the highly mutable HA1 head, it has become a primary target for the development of universal influenza vaccines and broadly neutralizing antibodies [Throsby et al., 2008]. Therapeutic agents targeting this region, such as monoclonal antibodies CR6261 or MEDI8852, typically function by stabilizing the pre-fusion conformation and preventing the structural rearrangements necessary for fusion [Dreyfus et al., 2012]. Targeting the HA2 stem is particularly vital for pandemic preparedness against highly pathogenic avian influenza strains like H5N1 [Lappala et al., 2018]. Small molecule inhibitors like Umifenovir also interact with the HA stem to block the fusion transition [Kadam & Wilson, 2017]. Research into this target focuses on overcoming the immunodominance of the HA1 head to elicit a robust protective response against the stalk [Impagliazzo et al., 2015].
Stabilization of the pre-fusion conformation of hemagglutinin to prevent the pH-induced structural rearrangements required for membrane fusion and viral entry [Ekiert et al., 2009].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin subunit HA2 (HA2) (HA2).